107 institutions hold shares in Agile Therapeutics Inc. (AGRX), with 859.48k shares held by insiders accounting for 0.98% while institutional investors hold 50.30% of the company’s shares. The shares outstanding are 87.35M, and float is at 67.10M with Short Float at 3.55%. Institutions hold 49.81% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Perceptive Advisors Llc with over 15.92 million shares valued at $45.69 million. The investor’s holdings represent 18.21% of the AGRX Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 5.12 million shares valued at $14.7 million to account for 5.86% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 4.37 million shares representing 5.00% and valued at over $12.55 million, while Investor AB holds 4.01% of the shares totaling 3.51 million with a market value of $10.07 million.
Agile Therapeutics Inc. (NASDAQ: AGRX) is 2.44% higher on its value in year-to-date trading and has touched a low of $1.35 and a high of $3.89 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AGRX stock was last observed hovering at around $3.09 in the last trading session, with the day’s loss setting it -0.15% off its average median price target of $8.00 for the next 12 months. It is also 70.6% off the consensus price target high of $10.00 offered by 5 analysts, but current levels are 51.0% higher than the price target low of $6.00 for the same period.
Currently trading at $2.94, the stock is -6.24% and -1.64% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.99 million and changing -4.85% at the moment leaves the stock 1.06% off its SMA200. AGRX registered -3.61% loss for a year compared to 6-month gain of 1.03%. The firm has a 50-day simple moving average (SMA 50) of $3.0324 and a 200-day simple moving average (SMA200) of $3.0005.
The stock witnessed a 0.00% loss in the last 1 month and extending the period to 3 months gives it a 2.80%, and is -19.45% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.74% over the week and 6.81% over the month.
Distance from 52-week low is 117.78% and -24.42% from its 52-week high.
Agile Therapeutics Inc. (AGRX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Agile Therapeutics Inc. (AGRX) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.60, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Agile Therapeutics Inc. is expected to release its quarterly report on 05/10/2021 and quarterly earnings per share for the current quarter are estimated at -$0.22 with sales reaching $1.01M over the same period.The EPS is expected to grow by 34.70% this year.
Agile Therapeutics Inc. (AGRX) Insider Activity
A total of 4 insider transactions have happened at Agile Therapeutics Inc. (AGRX) in the last six months, with sales accounting for 0 and purchases happening 4 times. The most recent transaction is an insider purchase by Reilly Dennis, the company’s Chief Financial Officer. SEC filings show that Reilly Dennis bought 9,000 shares of the company’s common stock on Sep 28 at a price of $2.85 per share for a total of $25650.0. Following the purchase, the insider now owns 0.11 million shares.
Agile Therapeutics Inc. disclosed in a document filed with the SEC on Mar 13 that PERCEPTIVE ADVISORS LLC (10% Owner) bought a total of 1,000,000 shares of the company’s common stock. The trade occurred on Mar 13 and was made at $1.75 per share for $1.75 million. Following the transaction, the insider now directly holds 15.92 million shares of the AGRX stock.
Still, SEC filings show that on Mar 04, Reilly Dennis (Chief Financial Officer) acquired 25,000 shares at an average price of $2.35 for $58750.0. The insider now directly holds 25,000 shares of Agile Therapeutics Inc. (AGRX).
Agile Therapeutics Inc. (AGRX): Who are the competitors?
The company’s main competitors (and peers) include TherapeuticsMD Inc. (TXMD) that is trading -15.26% down over the past 12 months. Pfizer Inc. (PFE) is 3.21% up on the 1-year trading charts. Short interest in the company’s stock has fallen -25.63% from the last report on Dec 30, 2020 to stand at a total of 2.99 million short shares sold with a short interest ratio of 2.14.